Abstract
Targeted Radionuclide Therapies (TRTs) based on Auger emitting radionuclides have the potential to deliver extremely selective therapeutic payloads on the cellular level. However, to fully exploit this potential, suitable radionuclides need to be applied in combination with appropriate delivery systems. In this review, we summarize the state-of-the-art production, purification, chelation and applications of two promising candidates for Targeted Auger Therapy, namely antimony- 119 (119Sb) and mercury-197 (197Hg). Both radionuclides have great potential to become efficient tools for TRT. We also highlight our current progress on the production of both radionuclides at TRIUMF and the University of Wisconsin.
Keywords: Targeted radionuclide therapy (TRT), auger electrons, mercury-197 (197Hg), antimony-119 (119Sb), production, radiochemicalseparation, coordination, imaging, dosimetry.
Graphical Abstract
Current Radiopharmaceuticals
Title:Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119
Volume: 14 Issue: 4
Author(s): Parmissa Randhawa, Aeli P. Olson, Shaohuang Chen, Kaley Lexi Gower-Fry, Cornelia Hoehr*, Jonathan W. Engle*, Caterina F. Ramogida*Valery Radchenko*
Affiliation:
- Department of Life Sciences Division, TRIUMF, Vancouver, BC,Canada
- Department of Medical Physics and Radiology, University of Wisconsin, Madison, WI,United States
- Department of Chemistry, Simon Fraser University, Burnaby, BC,Canada
- Department of Life Sciences Division, TRIUMF, Vancouver, BC,Canada
Keywords: Targeted radionuclide therapy (TRT), auger electrons, mercury-197 (197Hg), antimony-119 (119Sb), production, radiochemicalseparation, coordination, imaging, dosimetry.
Abstract: Targeted Radionuclide Therapies (TRTs) based on Auger emitting radionuclides have the potential to deliver extremely selective therapeutic payloads on the cellular level. However, to fully exploit this potential, suitable radionuclides need to be applied in combination with appropriate delivery systems. In this review, we summarize the state-of-the-art production, purification, chelation and applications of two promising candidates for Targeted Auger Therapy, namely antimony- 119 (119Sb) and mercury-197 (197Hg). Both radionuclides have great potential to become efficient tools for TRT. We also highlight our current progress on the production of both radionuclides at TRIUMF and the University of Wisconsin.
Export Options
About this article
Cite this article as:
Randhawa Parmissa , Olson P. Aeli , Chen Shaohuang , Gower-Fry Lexi Kaley , Hoehr Cornelia *, Engle W. Jonathan *, Ramogida F. Caterina *, Radchenko Valery *, Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119, Current Radiopharmaceuticals 2021; 14 (4) . https://dx.doi.org/10.2174/1874471014999210111201630
DOI https://dx.doi.org/10.2174/1874471014999210111201630 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Regulatable Gene Expression Systems for Gene Therapy
Current Gene Therapy Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Mechanisms Underlying Beneficial Health Effects of Tea Catechins to Improve Insulin Resistance and Endothelial Dysfunction
Endocrine, Metabolic & Immune Disorders - Drug Targets Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Identification of Biomarkers and Functional Modules from Genomic Data in Stage-wise Breast Cancer
Current Bioinformatics Recently Patented Applications of Homologous Cellular and Extracellular Agents as Therapeutics or Targets for the Prevention of Restenosis Post- Angioplasty
Recent Patents on Cardiovascular Drug Discovery An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Bio-Distribution, Imaging Protocols and Diagnostic Accuracy of PET with Tracers of Lipogenesis in Imaging Prostate Cancer: a Comparison between 11C-Choline, 18FFluoroethylcholine and 18F-Methylcholine
Current Pharmaceutical Design UDP-Glucuronosyltransferases
Current Drug Metabolism The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Oxytocin - A Multifunctional Analgesic for Chronic Deep Tissue Pain
Current Pharmaceutical Design Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Subject Index to Volume 5
Current Drug Targets Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Current Pharmaceutical Design Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design